Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Linscomb & Williams Inc.

Linscomb & Williams Inc. lessened its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 14.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,051 shares of the biopharmaceutical company’s stock after selling 1,045 shares during the period. Linscomb & Williams Inc.’s holdings in Bristol-Myers Squibb were worth $310,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. NBC Securities Inc. acquired a new stake in Bristol-Myers Squibb during the 3rd quarter worth approximately $477,000. Assenagon Asset Management S.A. boosted its stake in shares of Bristol-Myers Squibb by 4.3% in the third quarter. Assenagon Asset Management S.A. now owns 95,081 shares of the biopharmaceutical company’s stock valued at $5,519,000 after buying an additional 3,907 shares in the last quarter. Versor Investments LP acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at about $681,000. Callan Capital LLC increased its stake in Bristol-Myers Squibb by 59.8% in the 3rd quarter. Callan Capital LLC now owns 5,609 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 2,099 shares in the last quarter. Finally, Childress Capital Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the third quarter valued at approximately $265,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Price Performance

NYSE:BMY traded down $0.30 during mid-day trading on Friday, reaching $41.24. 17,425,597 shares of the company’s stock were exchanged, compared to its average volume of 13,919,494. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. Bristol-Myers Squibb has a one year low of $41.07 and a one year high of $66.46. The business’s fifty day simple moving average is $47.80 and its two-hundred day simple moving average is $49.64.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company posted $2.05 EPS. Analysts forecast that Bristol-Myers Squibb will post 0.59 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 5.82%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of recent research reports. Barclays lowered their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. BMO Capital Markets dropped their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Finally, Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $60.00.

View Our Latest Stock Analysis on Bristol-Myers Squibb

Bristol-Myers Squibb Company Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.